Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Mar;10(3):QC21-4.
doi: 10.7860/JCDR/2016/16545.7516. Epub 2016 Mar 1.

A Randomised Controlled Trial Comparing the Efficacy and Side-Effects of Intravaginal Ring (Nuvaring(®)) With Combined Oral Hormonal Preparation in Dysfunctional Uterine Bleeding

Sandhya Jain  1 , Neelam B Vaid  2 , Yam Narang  3 , Amita Suneja  2 , Kiran Guleria  2
Affiliations

A Randomised Controlled Trial Comparing the Efficacy and Side-Effects of Intravaginal Ring (Nuvaring(®)) With Combined Oral Hormonal Preparation in Dysfunctional Uterine Bleeding

Sandhya Jain et al. J Clin Diagn Res. 2016 Mar.

Abstract

Introduction: Combined Oral Contraceptive (COC) pills are being used in patients of abnormal uterine bleeding, especially adolescents and reproductive age women considering their need for contraception. It decreases the blood loss due to haemostatic effect of estrogen and also regularizes the cycle. Intravaginal route has been found to be effective and acceptable; Gastrointestinal absorption and hepatic first-pass metabolism is avoided and steady, uniform blood concentration is achieved. Bioavailability of estrogen and progestogen through oral and vaginal route are same. The convenience of once-a-month administration is another major advantage.

Materials and mathods: Sixty women fulfilling inclusion criteria were randomised into 2 groups in 1:1 ratio. In one group (n=30), monthly insertion of Nuvaring(®)) was done for three consecutive months. Nuvaring(®) releases 15μg ethinyl estradiol and 120 μg etonogesterol daily. The other group (n=30) received COC pill containing 30μg EE and 150 μg levonorgestrel for three consecutive months. Primary outcome measures were change in menstrual cycle pattern and pictorial Blood Loss Assessment chart (PBAC) score. Other Parameters included side effects, change in haemoglobin and weight. Data was analyzed by statistical software SPSS 20.

Results: Both Nuvaring(®) and COC were found to significantly decrease blood loss in each cycle. Decrease in PBAC score was more in Nuvaring(®) group compared to COC, however difference was not significant. Ideal bleed (IB) was frequently higher for Nuvaring(®) group than COC in all 3 cycles, although no statistically significant difference was observed between groups (p-value=0.286). Late withdrawl, intermenstural spotting was higher in COC group. Compliance was better and women were more satisfied in Nuvaring(®) group compared to COC group. Minor side effects like headache, mastalgia, nausea and mood changes were seen in both groups, which were not significant. Continuation rate was significantly higher in Nuvaring® group. 30% women discontinued treatment in OCP group after 3 month compare to 10% in Nuvaring(®) group.

Conclusion: Present study shows Nuvaring(®) to be as effective as COC in controlling heavy menstural bleed, better cycle control, with minor acceptable systemic side effects.

Keywords: Abnormal uterine bleeding; Cycle control; Nuvaring; Oral contraceptive pills.

PubMed Disclaimer

Figures

[Table/Fig-3]:
[Table/Fig-3]:
Trend of Mean Blood Loss in Nuvaring and OCP.
[Table/Fig-5]:
[Table/Fig-5]:
Patterns of menstrual flow. Cycle-wise menstrual pattern
See this image and copyright information in PMC

References

    1. Roumen FJME, Dieben TOM. Comparison of uterine concentrations of ethinylestradiol and etonogestrel – after use of a contraceptive vaginal ring and an oral contraceptive. Fertil Steril. 2006;85:57–62. - PubMed
    1. Bradley LD, Gueye NA. The medical management of abnormal uterine bleeding in reproductive-aged women. Am J Obstet Gynaecol. 2016;214:31–44. DOI: http://dx.doi.org/10.1016/j.ajog.2015.07.044. - PubMed
    1. Marret H, et al. Clinical practice guidelines on menorrhagia: management of abnormal uterine bleeding before menopause. Eur J Obstet Gynecol. 2010;152(2):133–37. doi:10.1016/j.ejogrb.2010.07.016. - PubMed
    1. Roumen FJME. Review of the combined contraceptive vaginal ring, Nuvaring. Therapeutics and Clinical Risk Management. 2008;4(2):441–51. - PMC - PubMed
    1. Timmer CJ, Mulders TMT. Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring. Clin Pharmacokinet. 2000;39:233–42. - PubMed

LinkOut - more resources